HROW — Harrow Health, Inc.

Harrow Health, Inc. (HROW) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $89.1 million, a 33% increase year-over-year.
• Full Year 2025 Revenue: $272 million, up 36% from 2024.
• Adjusted EBITDA: $24.2 million in Q4 and $61.9 million for the full year, reflecting a 54% year-over-year growth.
• Cash from Operations: Approximately $44 million, ending the year with $72.9 million in cash and cash equivalents.

2. Strategic Updates and Business Highlights

• Harrow Health has transformed into a leading player in the U.S. ophthalmic market, integrating over 15 branded products into its portfolio.
• VEVYE: Positioned for significant revenue growth with expanded payer coverage and plans to double the sales force, targeting a peak sales potential that could exceed previous years.
• IHEEZO: Achieved record revenue of $35.9 million in Q4, with plans for price improvements and expansion into office-based procedures.
• TRIESENCE: Strong adoption in ocular inflammation, with a 36% quarter-over-quarter revenue increase. Plans to double the sales force to enhance market penetration.
• Rare Specialty and Compounded Products: New leadership and resources are expected to unlock value in this segment, with several key products awaiting coding decisions and study results.
• Upcoming product launches include BYQLOVI and BYOOVIZ, aimed at expanding their retina and specialty portfolio.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $350 million and $365 million, with Q1 anticipated to be the lowest revenue quarter due to inventory adjustments and seasonal dynamics.
• Adjusted EBITDA for 2026: Projected between $80 million to $100 million, with stronger performance expected in the second half of the year.
• Strategic Focus: Continued investment in sales force expansion and marketing, particularly for VEVYE and TRIESENCE, while maintaining a disciplined approach to spending.

4. Bad News, Challenges, or Points of Concern

• First Quarter 2026 Challenges: Anticipated lower revenue due to inventory drawdown and the expiration of IHEEZO's ASC pass-through status, which could impact unit demand.
• Market Competition: Increased competition in the dry eye market and the need to effectively differentiate products in a crowded landscape.
• Regulatory Risks: Ongoing dependency on successful FDA approvals for new products like G-MELT and the potential for delays in market entry.

5. Notable Q&A Insights

• VEVYE Growth: The company is optimistic about capturing market share in the dry eye category, with a focus on converting cash-paying patients to covered patients due to expanded insurance access.
• IHEEZO Pricing and Demand: Expected price improvements in the second half of 2026, with ongoing clinical studies aimed at reinforcing the product's market position.
• Sales Force Dynamics: The expansion of the sales force is seen as critical for driving new prescriptions, with a significant focus on both ophthalmology and optometry markets.
• TRIESENCE Market Potential: The product is positioned for significant growth, with expectations that it will not be limited by temporary reimbursement codes due to its unique label.

Overall, Harrow Health, Inc. is poised for growth with a diversified portfolio and strategic initiatives aimed at expanding market presence, despite facing some near-term challenges and competitive pressures.